A Phase 3 interventional study of Abatacept and Placebo in Juvenile Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 36 sites in 11 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-01-18.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Arthritis, Juvenile with a site in United States — 20 open to participants now, 23 under way, 5 of them phase 3. Arthritis, Juvenile · United States.
Among the 109 studies in Arthritis, Juvenile with a site in United States, this one is the 10th largest by enrollment of the 83 interventional ones that give a count, is the only one that started in 2003, is one of 30 in phase 3, and was the 11th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →20 of the 109 studies in Arthritis, Juvenile with a site in United States are open now. Recruiting first, the newest first:
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages up to 35
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
Duke University · Sites in United States, Germany, Italy and 1 more country
Ages 2–21
NYU Langone Health · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Canada, France and 5 more countries
Ages 1+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 18 · Phase 3 32 · Phase 4 7
First in 1994; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 214 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 55 across the 83 interventional studies, 288 across the 24 observational. Of the 75 that completed or were terminated, 46 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 109 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 6 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
2 of the studies in Arthritis, Juvenile with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT07203001Novartis PharmaceuticalsA Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | 2027-04-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 109 studies in Arthritis, Juvenile with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept). In addition, the study will assess the effectiveness of BMS-188667 in reducing disease activity of Juvenile Rheumatoid Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) as measured by the time to occurrence of disease flare.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double Blind Period
Drug: Abatacept
Double Blind Period
Drug: Placebo
Drug: Abatacept
IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier).
Also known as: Orencia
IV infusions, IV, N/A, every 4 weeks, 6 months.
Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing \< 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing \> 100 kg, monthly
Also known as: Orencia
Time to Occurrence of Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease Flare During Double-Blind Phase (Period B)
Time to flare is defined as the elapsed number of days between the first dose date in Period B and the study day that disease flare is confirmed. All of the following criteria must be met to be defined as a flare: * \> 30% worsening in at least 3 of the 6 JRA/JIA core response variables * \> 30% improvement in not more than 1 of the 6 JRA/JIA core set variables * ≥ 2 cm of worsening must be present if the Physician or Parent Global Assessment is used to define flare * worsening in ≥ 2 joints must be present if the number of active joints or joints with limitation of motion is used to define flare based on changes in the surrogate marker, erythrocyte sedimentation rate (ESR)
Time frame: Period B (Day 113 to Day 282)
Number of Participants With a Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease With a Flare During Double-Blind Phase (Period B)
All of the following criteria must be met to be defined as a flare: * \> 30% worsening in at least 3 of the 6 JRA/JIA core response variables * \> 30% improvement in not more than 1 of the 6 JRA/JIA core set variables * ≥ 2 cm of worsening must be present if the Physician or Parent Global Assessment is used to define flare * worsening in ≥ 2 joints must be present if the number of active joints or joints with limitation of motion is used to define flare based on changes in the surrogate marker, erythrocyte sedimentation rate (ESR)
Time frame: Period B (Day 113 to Day 282)
Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Open-Label Lead-In Phase (Period A)
AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v14.1).
Time frame: Period A (Day 1 to Day 113)
Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Double-Blind Phase (Period B)
AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v14.1).
Time frame: Period B (Day 113 to Day 282)
Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Open-Label Phase (Period C)
AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 85 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v14.1).
Time frame: Period C (Day 282 to end of study)
Median Percent Change From Baseline in JRA/JIA Core Set Variables During Double-Blind Phase (Period B)
Percent change from baseline was calculated from the difference between post-baseline and baseline divided by baseline multiplied by 100 and reported as the range between 25th and 75th percentile, not full range; American College of Rheumatology (ACR) Pediatric 30 JRA/JIA core set variables include active joints, limited range of motion, physician global assessment of disease severity, parent global assessment of overall well-being, change in physical function as measured by the Childhood Health Assessment Questionnaire (CHAQ), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Disease activity was assessed by the physician and parent on a 0-100 mm visual analog scale (VAS). Low values represent low severity of disease and good well-being whereas high values represent highly severe disease and very poor well-being.
Time frame: Period B (Day 113 to Day 282)
Median Percent Change From Baseline in JRA/JIA Core Set Variables During Open-Label Phase (Period C)
Percent change from baseline was calculated from the difference between post-baseline and baseline divided by baseline multiplied by 100 and reported as the range between 25th and 75th percentile, not full range; American College of Rheumatology (ACR) Pediatric 30 JRA/JIA core set variables include active joints, limited range of motion, physician's global assessment of disease severity, parent global assessment of overall well-being, change in physical function as measured by the Childhood Health Assessment Questionnaire (CHAQ), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Disease activity was assessed by the physician and parent on a 0-100 mm visual analog scale (VAS). Low values represent low severity of disease and good well-being whereas high values represent highly severe disease and very poor well-being.
Time frame: Period C (Day 282 to end of study)
Events of Special Interest During Open-Label Lead-In Phase (Period A), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies
The sponsor prospectively identified categories of AEs that may be associated with the use of immunomodulatory drugs including infections, peri-infusional AEs, autoimmune disorders, malignancies. Peri-infusional AEs are defined as those AEs of special interest occurring during the first 24 hours after the start of study drug infusion. Malignancies definitions were based on events in the MedDRA Maintenance and Support Services Organization (MSSO) malignancies Structured MedDRA Query (SMQ).Autoimmune disorders are in alignment with the pre-specified MedDRA codes of autoimmune disorders events of interest.
Time frame: Period A (Day 1 to Day 113)
Events of Special Interest During Double-Blind Phase (Period B), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies
The sponsor prospectively identified categories of AEs that may be associated with the use of immunomodulatory drugs including infections, peri-infusional AEs, autoimmune disorders, malignancies. Peri-infusional AEs are defined as those AEs of special interest occurring during the first 24 hours after the start of study drug infusion. Malignancies definitions were based on events in the MedDRA Maintenance and Support Services Organization (MSSO) malignancies Structured MedDRA Query (SMQ).Autoimmune disorders are in alignment with the pre-specified MedDRA codes of autoimmune disorders events of interest.
Time frame: Period B (Day 113 to Day 282)
Events of Special Interest During Open-Label Phase (Period C), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies
The sponsor prospectively identified categories of AEs that may be associated with the use of immunomodulatory drugs including infections, peri-infusional AEs, autoimmune disorders, malignancies. Peri-infusional AEs are defined as those AEs of special interest occurring during the first 24 hours after the start of study drug infusion. Malignancies definitions were based on events in the MedDRA Maintenance and Support Services Organization (MSSO) malignancies Structured MedDRA Query (SMQ).Autoimmune disorders are in alignment with the pre-specified MedDRA codes of autoimmune disorders events of interest.
Time frame: Period C (Day 282 up to 56 days after the last dose of study medication)
Percentage of Participants Achieving American College of Rheumatology (ACR) Pediatric 30 (ACRP30), ACR Pediatric 50, ACR Pediatric 70, ACR Pediatric 90, and Inactive Disease Status Erythrocyte Sedimentation Rate (ESR) Response Rate
The ACRP30 response criteria were defined as a ≥ 30% improvement over baseline in ESR. ACRP 50, 70, and 90 responses were defined similarly with 50%, 70%, and 90% improvements required, respectively.
Time frame: Day 113, Day 282, and Day 2047
Number of Treated Participants With Marked Laboratory Abnormalities During Open-Label Lead-In Phase (Period A)
Marked abnormalities were pre-defined as changes in lab tests that occurred after drug infusion and were reported relative to the normal range for each analyte. Hemoglobin, 11.6-14.8 grams per deciliter (g/dL);Hematocrit, 36.0-50.0 percent;Erythrocytes, 3.80-5.10x10\*6 cells per microliter (c/uL);Platelets, 140-44 cells per liter (c/L);Leukocytes, 4.00-12.50 c/uL;Absolute Neutrophils + Bands, if \<1.00x10\^3 c/uL;Absolute Lymphocytes, if \<0.72x10\^3 or \>7.50x10\^3 c/uL;Absolute Eosinophils, if \>0.750X10\^3 c/uL;Alanine Aminotransferase, 0-40 units per liter (U/L);G-Glutamyl Transferase, 0-60 U/L;Bilirubin, 0.1-1.2 milligrams per deciliter (mg/dL);Blood Urea Nitrogen, 5.9-26.0 mg/dL;Creatinine, 0.50-1.50 mg/dL;Serum Potassium, 3.5-5.5 milliequivalents per liter (mEq/L);Serum Glucose, 65-99 mg/dL;Fasting Serum Glucose, 65-99 mg/dL;Total Protein, 6.0-8.5 g/dL;Albumin, 3.5-5.5 g/dL;Urine Protein, \>=4;Urine Glucose, \>=4;Urine Blood, \>=4;Urine Red Blood Cells \>=4;Urine White Blood Cells, \>=4.
Time frame: Period A (Day 1 to Day 113)
Number of Treated Participants With Marked Laboratory Abnormalities During Double-Blind Phase (Period B)
Marked abnormalities were pre-defined as changes in lab tests that occurred after drug infusion and were reported relative to the normal range for each analyte. Hemoglobin, 11.6-14.8 grams per deciliter (g/dL);Hematocrit, 36.0-50.0 percent;Erythrocytes, 3.80-5.10x10\*6 cells per microliter (c/uL);Platelets, 140-44 cells per liter (c/L);Leukocytes, 4.00-12.50 c/uL;Absolute Neutrophils + Bands, if \<1.00x10\^3 c/uL;Absolute Lymphocytes, if \<0.72x10\^3 or \>7.50x10\^3 c/uL;Absolute Eosinophils, if \>0.750X10\^3 c/uL;Aspartate Aminotransferase, 0-40 units per liter (U/L); Alanine Aminotransferase, 0-40 U/L;Blood Urea Nitrogen, 5.9-26.0 mg/dL;Serum Sodium, 135-148 milliequivalents per liter (mEq/L);Serum Potassium, 3.5-5.5 mEq/L;Serum Glucose, 65-99 mg/dL;Fasting Serum Glucose, 65-99 mg/dL;Urine Protein, \>=4;Urine Blood, \>=4;Urine Red Blood Cells \>=4;Urine White Blood Cells, \>=4.
Time frame: Period B (Day 113 to Day 282)
Number of Treated Participants With Marked Laboratory Abnormalities During Open-Label Phase (Period C)
Marked abnormalities were pre-defined as changes in lab tests after drug infusion and relative to normal range. Hemoglobin,11.6-14.8grams per deciliter(g/dL);Hematocrit,36.0-50.0 percent;Erythrocytes,3.80-5.10x10\*6 cells per microliter(c/uL);Platelets,140-44 cells per liter(c/L);Leukocytes,4.00-12.50c/uL;Absolute(Abs)Neutrophils+Bands,\<1.00x10\^3 c/uL;Abs Lymphocytes,\<0.72x10\^3 or\>7.50x10\^3 c/uL;Abs Eosinophils,\>0.750X10\^3 c/uL;Alkaline Phosphatase,0-40 units per liter(U/L);Aspartate Aminotransferase,0-40 U/L;Alanine Aminotransferase,0-40U/L;G-Glutamyl Transferase,0-60 U/L;Bilirubin, 0.1-1.2 milligrams per deciliter(mg/dL);Blood Urea Nitrogen,5.9-26.0 mg/dL;Creatinine, 0.50-1.50mg/dL;Inorganic Phosphorus,2.8-6.2 U/L;Serum Potassium,3.5-5.5 milliequivalents per liter(mEq/L);Serum Glucose,65-99 mg/dL;Fasting Serum Glucose,65-99 mg/dL;Total Protein, 6.0-8.5 g/dL;Albumin,3.5-5.5 g/dL;Urine Protein,\>=4;Urine Glucose,\>=4;Urine Blood,\>=4;Urine Red Blood Cells\>=4;Urine White Blood Cells,\>=4.
Time frame: Period C (Day 282 to end of study)
Number of Participants With Anti-Abatacept or Anti-CTLA4 Positive Responses Over Time During Open-Label Phase (Period C)
During Period C, blood samples for immunogenicity assessments were obtained just prior to the start of the IV infusion of abatacept at 3-month intervals during the first 2 years of Period C, at 6-month intervals thereafter, and again 28, 56, and 85 days after the last infusion. Direct-format, enzyme-linked immunosorbent assays (ELISAs) were used to evaluate the cytotoxic T-lymphocyte antigen 4 (CTLA4) and the anti-CTLA4-T antibody.
Time frame: Period C (Day 282 to 85 days after the last dose of study medication)
| Milestone | Abatacept (All Participants in Period A) | Abatacept (Period B) | Placebo (Period B) | Abatacept (Period A Non-Responders in Period C) | Abatacept (Period C) | Placebo (Period B) to Abatacept (Period C) |
|---|---|---|---|---|---|---|
| Started | 190 | 0 | 0 | 0 | 0 | 0 |
| Completed | 170 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 20 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 17 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Abatacept (All Participants in Period A) | Abatacept (Period B) | Placebo (Period B) | Abatacept (Period A Non-Responders in Period C) | Abatacept (Period C) | Placebo (Period B) to Abatacept (Period C) |
|---|---|---|---|---|---|---|
| Started | 0 | 60 | 62 | 0 | 0 | 0 |
| Completed | 0 | 49 | 31 | 0 | 0 | 0 |
| Not completed | 0 | 11 | 31 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 10 | 31 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Abatacept (All Participants in Period A) | Abatacept (Period B) | Placebo (Period B) | Abatacept (Period A Non-Responders in Period C) | Abatacept (Period C) | Placebo (Period B) to Abatacept (Period C) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 36 | 58 | 59 |
| Completed | 0 | 0 | 0 | 13 | 29 | 27 |
| Not completed | 0 | 0 | 0 | 23 | 29 | 32 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 2 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 11 | 5 | 8 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 5 | 6 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 4 | 6 | 0 |
| Withdrew: No longer meets study criteria | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Poor/non-compliance | 0 | 0 | 0 | 0 | 2 | 2 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 | 2 | 3 |
| Withdrew: Other | 0 | 0 | 0 | 4 | 6 | 8 |
Time to flare is defined as the elapsed number of days between the first dose date in Period B and the study day that disease flare is confirmed. All of the following criteria must be met to be defined as a flare: * \> 30% worsening in at least 3 of the 6 JRA/JIA core response variables * \> 30% improvement in not more than 1 of the 6 JRA/JIA core set variables * ≥ 2 cm of worsening must be present if the Physician or Parent Global Assessment is used to define flare * worsening in ≥ 2 joints must be present if the number of active joints or joints with limitation of motion is used to define flare based on changes in the surrogate marker, erythrocyte sedimentation rate (ESR)
| months | Abatacept (Period B) | Placebo (Period B) |
|---|---|---|
| Time to Occurrence of Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease Flare During Double-Blind Phase (Period B) | NA (NA to NA) | 6 (0.73 to 6.87) |
All of the following criteria must be met to be defined as a flare: * \> 30% worsening in at least 3 of the 6 JRA/JIA core response variables * \> 30% improvement in not more than 1 of the 6 JRA/JIA core set variables * ≥ 2 cm of worsening must be present if the Physician or Parent Global Assessment is used to define flare * worsening in ≥ 2 joints must be present if the number of active joints or joints with limitation of motion is used to define flare based on changes in the surrogate marker, erythrocyte sedimentation rate (ESR)
| participants | Abatacept (Period B) | Placebo (Period B) |
|---|---|---|
| Number of Participants With a Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease With a Flare During Double-Blind Phase (Period B) | 12 | 33 |
AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v14.1).
| participants | Abatacept (All Participants in Period A) |
|---|---|
| SAE | 6 |
| Treatment-Related AE | 0 |
| All Deaths | 0 |
| Treatment-Related Deaths | 0 |
| Discontinuation of Study Drug due to AEs | 1 |
AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v14.1).
| participants | Abatacept (Period B) | Placebo (Period B) |
|---|---|---|
| SAE | 0 | 2 |
| Treatment-Related AE | 0 | 0 |
| All Deaths | 0 | 0 |
| Treatment-Related Deaths | 0 | 0 |
| Discontinuation of Study Drug due to AEs | 0 | 0 |
AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 85 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v14.1).
| participants | Abatacept (Period A Non-Responders in Period C) | Abatacept (Period C) | Placebo (Period B) to Abatacept (Period C) |
|---|---|---|---|
| SAE | 9 | 9 | 12 |
| Treatment-Related AE | 2 | 4 | 3 |
| All Deaths | 0 | 0 | 1 |
| Treatment-Related Deaths | 0 | 0 | 0 |
| Discontinuation of Study Drug due to AEs | 1 | 2 | 3 |
Percent change from baseline was calculated from the difference between post-baseline and baseline divided by baseline multiplied by 100 and reported as the range between 25th and 75th percentile, not full range; American College of Rheumatology (ACR) Pediatric 30 JRA/JIA core set variables include active joints, limited range of motion, physician global assessment of disease severity, parent global assessment of overall well-being, change in physical function as measured by the Childhood Health Assessment Questionnaire (CHAQ), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Disease activity was assessed by the physician and parent on a 0-100 mm visual analog scale (VAS). Low values represent low severity of disease and good well-being whereas high values represent highly severe disease and very poor well-being.
| percentage change from baseline | Abatacept (Period B) | Placebo (Period B) |
|---|---|---|
| Active Joints | -20.9 (-92.0 to 17.86) | 50.00 (0.00 to 100.0) |
| Joints with LOM | 0.00 (-45.5 to 0.00) | 50.00 (0.00 to 100.0) |
| Physician Global Assessment | -29.8 (-86.3 to 22.48) | 55.95 (-31.3 to 250.0) |
| Parent Global Assessment | -11.2 (-56.8 to 28.41) | 8.39 (-31.8 to 100.0) |
| CHAQ Disability Index | 0.00 (-38.9 to 2.17) | 0.00 (-13.3 to 55.56) |
| ESR | 0.00 (-20.7 to 50.00) | 20.50 (-14.3 to 92.00) |
| CRP | 0.00 (-46.6 to 67.00) | 6.25 (-33.3 to 150.0) |
Percent change from baseline was calculated from the difference between post-baseline and baseline divided by baseline multiplied by 100 and reported as the range between 25th and 75th percentile, not full range; American College of Rheumatology (ACR) Pediatric 30 JRA/JIA core set variables include active joints, limited range of motion, physician's global assessment of disease severity, parent global assessment of overall well-being, change in physical function as measured by the Childhood Health Assessment Questionnaire (CHAQ), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Disease activity was assessed by the physician and parent on a 0-100 mm visual analog scale (VAS). Low values represent low severity of disease and good well-being whereas high values represent highly severe disease and very poor well-being.
| percentage change from baseline | Abatacept (Period A Non-Responders in Period C) | Abatacept (Period C) | Placebo (Period B) to Abatacept (Period C) |
|---|---|---|---|
| Active Joints | -26.7 (-66.7 to 0.00) | -70.2 (-94.1 to -50.0) | -82.4 (-100 to -62.5) |
| Joints with Limited Range of Motion | 0.00 (-33.3 to 36.67) | -50.0 (-75.0 to -27.3) | -71.4 (-86.2 to -23.1) |
| Physician Global Assessment of Disease Severity | -31.9 (-50.0 to -9.33) | -75.0 (-91.3 to -52.3) | -81.8 (-91.4 to -64.3) |
| Parent Global Assessment of Overall Well-Being | 1.96 (-19.6 to 26.67) | -62.7 (-93.8 to -27.5) | -63.9 (-84.2 to -38.8) |
| CHAQ Disability Index | 14.14 (-16.7 to 100.0) | -56.7 (-81.8 to -18.2) | -45.5 (-75.0 to -12.5) |
| ESR | 20.87 (-15.5 to 83.77) | -27.3 (-54.8 to 20.00) | -24.2 (-50.0 to 0.00) |
| CRP | 0.00 (-31.6 to 43.68) | -33.8 (-84.4 to 54.84) | -27.8 (-75.0 to 11.11) |
The sponsor prospectively identified categories of AEs that may be associated with the use of immunomodulatory drugs including infections, peri-infusional AEs, autoimmune disorders, malignancies. Peri-infusional AEs are defined as those AEs of special interest occurring during the first 24 hours after the start of study drug infusion. Malignancies definitions were based on events in the MedDRA Maintenance and Support Services Organization (MSSO) malignancies Structured MedDRA Query (SMQ).Autoimmune disorders are in alignment with the pre-specified MedDRA codes of autoimmune disorders events of interest.
| participants | Abatacept (All Participants in Period A) |
|---|---|
| Infections and Infestations | 68 |
| Peri-Infusional AEs | 30 |
| Autoimmune Disorders | 2 |
| Malignancies | 0 |
The sponsor prospectively identified categories of AEs that may be associated with the use of immunomodulatory drugs including infections, peri-infusional AEs, autoimmune disorders, malignancies. Peri-infusional AEs are defined as those AEs of special interest occurring during the first 24 hours after the start of study drug infusion. Malignancies definitions were based on events in the MedDRA Maintenance and Support Services Organization (MSSO) malignancies Structured MedDRA Query (SMQ).Autoimmune disorders are in alignment with the pre-specified MedDRA codes of autoimmune disorders events of interest.
| participants | Abatacept (Period B) | Placebo (Period B) |
|---|---|---|
| Infections and Infestations | 27 | 27 |
| Peri-Infusional AEs | 2 | 2 |
| Autoimmune Disorders | 0 | 0 |
| Malignancies | 0 | 0 |
The sponsor prospectively identified categories of AEs that may be associated with the use of immunomodulatory drugs including infections, peri-infusional AEs, autoimmune disorders, malignancies. Peri-infusional AEs are defined as those AEs of special interest occurring during the first 24 hours after the start of study drug infusion. Malignancies definitions were based on events in the MedDRA Maintenance and Support Services Organization (MSSO) malignancies Structured MedDRA Query (SMQ).Autoimmune disorders are in alignment with the pre-specified MedDRA codes of autoimmune disorders events of interest.
| participants | Abatacept (All Participants in Period C) |
|---|---|
| Infections and Infestations | 120 |
| Peri-Infusional AEs | 22 |
| Autoimmune Disorders | 7 |
| Malignancies | 1 |
The ACRP30 response criteria were defined as a ≥ 30% improvement over baseline in ESR. ACRP 50, 70, and 90 responses were defined similarly with 50%, 70%, and 90% improvements required, respectively.
| percentage of participants | Abatacept (Period A Non-Responders in Period C) | Abatacept (Period C) | Placebo (Period B) to Abatacept (Period C) |
|---|---|---|---|
| ACR Pediatric 30 (ESR) at Day 113 | 0 (NA to NA) | 100 (NA to NA) | 100 (NA to NA) |
| ACR Pediatric 30 (ESR) at Day 282 | NA (NA to NA) | 84.5 (75.2 to 93.8) | 67.8 (55.9 to 79.7) |
| ACR Pediatric 30 (ESR) at Day 2047 | 69.2 (44.1 to 94.3) | 97.0 (91.1 to 100) | 86.7 (74.5 to 98.8) |
| ACR Pediatric 50 (ESR) at Day 113 | 0 (NA to NA) | 65.5 (53.3 to 77.7) | 88.1 (79.9 to 96.4) |
| ACR Pediatric 50 (ESR) at Day 282 | NA (NA to NA) | 79.3 (68.9 to 89.7) | 52.5 (39.8 to 65.3) |
| ACR Pediatric 50 (ESR) at Day 2047 | 69.2 (44.1 to 94.3) | 93.9 (85.8 to 100.0) | 80.0 (65.7 to 94.3) |
| ACR Pediatric 70 (ESR) at Day 113 | 0 (NA to NA) | 37.9 (25.4 to 50.4) | 49.2 (36.4 to 61.9) |
| ACR Pediatric 70 (ESR) at Day 282 | NA (NA to NA) | 55.2 (42.4 to 68.0) | 30.5 (18.8 to 42.3) |
| ACR Pediatric 70 (ESR) at Day 2047 | 53.8 (26.7 to 80.9) | 78.8 (64.8 to 92.7) | 63.3 (46.1 to 80.6) |
| ACR Pediatric 90 (ESR) at Day 113 | 0 (NA to NA) | 17.2 (7.5 to 27.0) | 22.0 (11.5 to 32.6) |
| ACR Pediatric 90 (ESR) at Day 282 | NA (NA to NA) | 41.4 (28.7 to 54.1) | 15.3 (6.1 to 24.4) |
| ACR Pediatric 90 (ESR) at Day 2047 | 38.5 (12.0 to 64.9) | 66.7 (50.6 to 82.8) | 40.0 (22.5 to 57.5) |
Marked abnormalities were pre-defined as changes in lab tests that occurred after drug infusion and were reported relative to the normal range for each analyte. Hemoglobin, 11.6-14.8 grams per deciliter (g/dL);Hematocrit, 36.0-50.0 percent;Erythrocytes, 3.80-5.10x10\*6 cells per microliter (c/uL);Platelets, 140-44 cells per liter (c/L);Leukocytes, 4.00-12.50 c/uL;Absolute Neutrophils + Bands, if \<1.00x10\^3 c/uL;Absolute Lymphocytes, if \<0.72x10\^3 or \>7.50x10\^3 c/uL;Absolute Eosinophils, if \>0.750X10\^3 c/uL;Alanine Aminotransferase, 0-40 units per liter (U/L);G-Glutamyl Transferase, 0-60 U/L;Bilirubin, 0.1-1.2 milligrams per deciliter (mg/dL);Blood Urea Nitrogen, 5.9-26.0 mg/dL;Creatinine, 0.50-1.50 mg/dL;Serum Potassium, 3.5-5.5 milliequivalents per liter (mEq/L);Serum Glucose, 65-99 mg/dL;Fasting Serum Glucose, 65-99 mg/dL;Total Protein, 6.0-8.5 g/dL;Albumin, 3.5-5.5 g/dL;Urine Protein, \>=4;Urine Glucose, \>=4;Urine Blood, \>=4;Urine Red Blood Cells \>=4;Urine White Blood Cells, \>=4.
| participants | Abatacept (All Participants in Period A) |
|---|---|
| Hemoglobin (Low) n=189 | 2 |
| Hematocrit (Low) n=189 | 2 |
| Erythrocytes (Low) n=189 | 1 |
| Platelets (Low) n=189 | 1 |
| Platelet Count (High) n=189 | 2 |
| Leukocytes (Low) n=189 | 9 |
| Leukocytes (High) n=189 | 10 |
| Absolute Neutrophils + Bands (Low) n=189 | 5 |
| Absolute Lymphocytes (Low) n=189 | 9 |
| Absolute Eosinophils (High) n=189 | 16 |
| Alanine Aminotransferase (ALT, High) n=190 | 2 |
| G-Glutamyl Transferase (GGT, High) n=190 | 1 |
| Bilirubin (Total, High) n=190 | 1 |
| Blood Urea Nitrogen (High) n=190 | 6 |
| Creatinine (High) n=190 | 12 |
| Potassium (High) n=190 | 4 |
| Serum Glucose (Low) n=190 | 26 |
| Serum Glucose (High) n=190 | 2 |
| Fasting Serum Glucose (High) n=109 | 1 |
| Total Protein (High) n=190 | 2 |
| Albumin (Low) n=190 | 2 |
| Urine Protein (High) n=190 | 12 |
| Urine Glucose (High) n=190 | 1 |
| Urine Blood (High) n=190 | 23 |
| Urine White Blood Cells (High) n=75 | 9 |
| Urine Red Blood Cells (High) n=75 | 25 |
Marked abnormalities were pre-defined as changes in lab tests that occurred after drug infusion and were reported relative to the normal range for each analyte. Hemoglobin, 11.6-14.8 grams per deciliter (g/dL);Hematocrit, 36.0-50.0 percent;Erythrocytes, 3.80-5.10x10\*6 cells per microliter (c/uL);Platelets, 140-44 cells per liter (c/L);Leukocytes, 4.00-12.50 c/uL;Absolute Neutrophils + Bands, if \<1.00x10\^3 c/uL;Absolute Lymphocytes, if \<0.72x10\^3 or \>7.50x10\^3 c/uL;Absolute Eosinophils, if \>0.750X10\^3 c/uL;Aspartate Aminotransferase, 0-40 units per liter (U/L); Alanine Aminotransferase, 0-40 U/L;Blood Urea Nitrogen, 5.9-26.0 mg/dL;Serum Sodium, 135-148 milliequivalents per liter (mEq/L);Serum Potassium, 3.5-5.5 mEq/L;Serum Glucose, 65-99 mg/dL;Fasting Serum Glucose, 65-99 mg/dL;Urine Protein, \>=4;Urine Blood, \>=4;Urine Red Blood Cells \>=4;Urine White Blood Cells, \>=4.
| participants | Abatacept (Period B) | Placebo (Period B) |
|---|---|---|
| Hemoglobin (Low) n=60, 61 | 1 | 1 |
| Hematocrit (Low) n=60, 61 | 1 | 1 |
| Erythrocytes (Low) n=60, 61 | 0 | 1 |
| Platelets (Low) n-60, 61 | 4 | 0 |
| Platelets (High) n=189 | 0 | 1 |
| Leukocytes (Low) n=60, 61 | 1 | 1 |
| Leukocytes (High) n=60, 61 | 1 | 2 |
| Absolute Neutrophils + Bands (Low) n=60, 62 | 0 | 1 |
| Absolute Lymphocytes (Low) n=60, 62 | 2 | 3 |
| Absolute Eosinophils (High) n=60, 62 | 6 | 4 |
| Aspartate Aminotransferase (AST, High) n=60, 62 | 1 | 0 |
| Alanine Aminotransferase (ALT, High) n=60, 62 | 1 | 0 |
| Blood Urea Nitrogen (High) n=60, 62 | 1 | 1 |
| Serum Sodium (Low) n=60, 62 | 0 | 1 |
| Serum Potassium (High) n=60, 62 | 2 | 0 |
| Serum Glucose (Low) n=60, 62 | 4 | 5 |
| Serum Glucose (High) n=60, 62 | 0 | 1 |
| Fasting Serum Glucose (High) n=60, 62 | 1 | 1 |
| Urine Protein (High) n=62 | 2 | 2 |
| Urine Blood (High) n=60, 62 | 12 | 6 |
| Urine White Blood Cells (High) n=24, 20 | 5 | 2 |
| Urine Red Blood Cells (High) n=24, 20 | 6 | 4 |
Marked abnormalities were pre-defined as changes in lab tests after drug infusion and relative to normal range. Hemoglobin,11.6-14.8grams per deciliter(g/dL);Hematocrit,36.0-50.0 percent;Erythrocytes,3.80-5.10x10\*6 cells per microliter(c/uL);Platelets,140-44 cells per liter(c/L);Leukocytes,4.00-12.50c/uL;Absolute(Abs)Neutrophils+Bands,\<1.00x10\^3 c/uL;Abs Lymphocytes,\<0.72x10\^3 or\>7.50x10\^3 c/uL;Abs Eosinophils,\>0.750X10\^3 c/uL;Alkaline Phosphatase,0-40 units per liter(U/L);Aspartate Aminotransferase,0-40 U/L;Alanine Aminotransferase,0-40U/L;G-Glutamyl Transferase,0-60 U/L;Bilirubin, 0.1-1.2 milligrams per deciliter(mg/dL);Blood Urea Nitrogen,5.9-26.0 mg/dL;Creatinine, 0.50-1.50mg/dL;Inorganic Phosphorus,2.8-6.2 U/L;Serum Potassium,3.5-5.5 milliequivalents per liter(mEq/L);Serum Glucose,65-99 mg/dL;Fasting Serum Glucose,65-99 mg/dL;Total Protein, 6.0-8.5 g/dL;Albumin,3.5-5.5 g/dL;Urine Protein,\>=4;Urine Glucose,\>=4;Urine Blood,\>=4;Urine Red Blood Cells\>=4;Urine White Blood Cells,\>=4.
| participants | Abatacept (All Participants in Period C) |
|---|---|
| Hemoglobin (Low) n=153 | 12 |
| Hematocrit (Low) n=153 | 8 |
| Erythrocytes (Low) n=153 | 4 |
| Platelet Count (Low) n=153 | 4 |
| Platelet Count (High) n=153 | 5 |
| Leukocytes (Low) n=153 | 20 |
| Leukocytes (High) n=153 | 18 |
| Absolute Neutrophils + Bands (Low) | 14 |
| Absolute Lymphocytes (Low) n=153 | 21 |
| Absolute Lymphocytes (High) n=153 | 5 |
| Absolute Eosinophils (High) n=153 | 50 |
| Alkaline Phosphatase (ALP, High) n=153 | 2 |
| Aspartate Aminotransferase (AST, High) | 5 |
| Alanine Aminotransferase (ALT, High) n=153 | 11 |
| G-Glutamyl Transferase (GGT, High) n=153 | 6 |
| Bilirubin (Total, High) n=153 | 3 |
| Blood Urea Nitrogen (High) n=153 | 15 |
| Creatinine (High) n=153 | 36 |
| Potassium (High) n=153 | 10 |
| Inorganic Phosphorus (High) n=153 | 4 |
| Serum Glucose (Low) n=153 | 54 |
| Serum Glucose (High) n=153 | 1 |
| Fasting Serum Glucose (Low) n=100 | 11 |
| Fasting Serum Glucose (High) n=100 | 7 |
| Total Protein (Low) n=153 | 1 |
| Total Protein (High) n=153 | 1 |
| Albumin (Low) n=153 | 9 |
| Urine Protein (High) n=153 | 35 |
| Urine Glucose (High) n=153 | 1 |
| Urine Blood (High) n=153 | 73 |
| Urine White Blood Cells (High) n=117 | 49 |
| Urine Red Blood Cells (High) n=117 | 86 |
During Period C, blood samples for immunogenicity assessments were obtained just prior to the start of the IV infusion of abatacept at 3-month intervals during the first 2 years of Period C, at 6-month intervals thereafter, and again 28, 56, and 85 days after the last infusion. Direct-format, enzyme-linked immunosorbent assays (ELISAs) were used to evaluate the cytotoxic T-lymphocyte antigen 4 (CTLA4) and the anti-CTLA4-T antibody.
| participants | Abatacept (Period A Non-Responders in Period C) | Abatacept (Period C) | Placebo (Period B) to Abatacept (Period C) |
|---|---|---|---|
| Anti-Abatacept, Overall on Treatment (n=31,54,54) | 1 | 5 | 2 |
| Anti-Abatacept, Post-Treatment (n=25,41,38) | 0 | 3 | 3 |
| Anti-CTLA4-T, Overall on Treatment (n=33,57,58) | 4 | 4 | 4 |
| Anti-CTLA4-T, Overall Post-Treatment (n=27,46,42) | 4 | 1 | 1 |
Collected over From first dose to last dose plus 56 days up to end of study (November 2011). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abatacept (Only Period A) | — | 4/32 (12.5%) | 22/32 (68.8%) |
| Abatacept (Period A/Period C) | — | 10/36 (27.8%) | 32/36 (88.9%) |
| Abatacept (Period A/Period B) | — | 9/60 (15%) | 57/60 (95%) |
| Abatacept (Period A)/Placebo (Period B) | — | 14/62 (22.6%) | 54/62 (87.1%) |
| Event | Abatacept (Only Period A) | Abatacept (Period A/Period C) | Abatacept (Period A/Period B) | Abatacept (Period A)/Placebo (Period B) |
|---|---|---|---|---|
| ArthritisMusculoskeletal and connective tissue disorders | 0/32 | 3/36 | 3/60 | 0/62 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 2/32 | 1/36 | 0/60 | 1/62 |
| AppendicitisInfections and infestations | 0/32 | 0/36 | 2/60 | 0/62 |
| Ovarian cystReproductive system and breast disorders | 1/32 | 0/36 | 0/60 | 0/62 |
| Acute lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/32 | 0/36 | 0/60 | 0/62 |
| Abscess limbInfections and infestations | 0/32 | 1/36 | 0/60 | 0/62 |
| Condition aggravatedGeneral disorders | 0/32 | 1/36 | 0/60 | 0/62 |
| Herpes zosterInfections and infestations | 0/32 | 1/36 | 0/60 | 0/62 |
| Meningitis bacterialInfections and infestations | 0/32 | 1/36 | 0/60 | 0/62 |
| TorticollisMusculoskeletal and connective tissue disorders | 0/32 | 1/36 | 0/60 | 0/62 |
| Event | Abatacept (Only Period A) | Abatacept (Period A/Period C) | Abatacept (Period A/Period B) | Abatacept (Period A)/Placebo (Period B) |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 3/32 | 12/36 | 11/60 | 12/62 |
| NasopharyngitisInfections and infestations | 3/32 | 11/36 | 20/60 | 15/62 |
| HeadacheNervous system disorders | 7/32 | 10/36 | 14/60 | 11/62 |
| InfluenzaInfections and infestations | 1/32 | 6/36 | 16/60 | 12/62 |
| DiarrhoeaGastrointestinal disorders | 2/32 | 8/36 | 11/60 | 15/62 |
| PyrexiaGeneral disorders | 2/32 | 8/36 | 12/60 | 12/62 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/32 | 7/36 | 10/60 | 13/62 |
| PharyngitisInfections and infestations | 0/32 | 3/36 | 10/60 | 13/62 |
| VomitingGastrointestinal disorders | 2/32 | 7/36 | 9/60 | 13/62 |
| SinusitisInfections and infestations | 1/32 | 5/36 | 12/60 | 7/62 |
All treated participants in the Lead-In Phase (Period A)
| Age, Continuous(years) | Abatacept (All Participants in Period A) |
|---|---|
| Median | 13.0 (5.0 to 17.0) |
| Gender(Participants) | Abatacept (All Participants in Period A) |
|---|---|
| Female | 137 |
| Male | 53 |
The record gives a start of Dec 2003, a primary completion of Jun 2006 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 10 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept